drugset / Trial / NCT05560659
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Phase 2
Recruiting
92 enrolled
Peter MacCallum Cancer Centre, Australia
Varian Medical Systems · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
Timeline
- Start
- 2023-12-14
- Primary completion
- 2026-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUTETIUM LU 177 ZADAVOTIDE GURAXETAN | Other / unclassified | — | — |